Journal of Clinical Oncology最新文献

{"title":"Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.","authors":"Jennifer L Caswell-Jin, Mark R Somerfield, Muhammad Ali Khan, Gretchen G Kimmick, Shilpi Gupta, Kara Kenan, Namrata Peswani, Dawn L Hershman, Brenda J Ernst, Brittany E Harvey, Gregor Krings, Nicholas P McAndrew, Irbaz Bin Riaz, Ines Vaz-Luis, Cynthia Villarreal-Garza, Japneet Kaur Oberoi, Muhammad Hussnain Sadiq, Huan He, Ramaa Chitale, Michael J Hassett","doi":"10.1200/JCO-26-02034","DOIUrl":"https://doi.org/10.1200/JCO-26-02034","url":null,"abstract":"<p><strong>Purpose: </strong>To provide recommendations on use of medical therapies for patients with stage I-III hormone receptor-positive, HER2-negative breast cancer.</p><p><strong>Methods: </strong>An Expert Panel including patient representation completed a systematic review of the evidence and formulated recommendations for practice. Eligible studies included patients with stage I-III hormone receptor-positive, HER2-negative breast cancer and evaluated neoadjuvant or adjuvant chemotherapy, endocrine therapy, immunotherapy, or targeted therapy. Outcomes of interest included pathologic complete response, disease-free survival, distant recurrence-free survival, overall survival, health-related quality of life, and treatment-related adverse effects.</p><p><strong>Results: </strong>Forty-five randomized clinical trials (68 references) published from 2018-2026 were identified by the broad literature search. Supplemental searches identified six individual patient data meta-analyses and 21 retrospective studies that, combined with the primary clinical trials, informed guidance on which patients should receive treatment, which treatments should be selected, optimal treatment timing, duration of treatment, and approaches to support adherence. A final section addresses estimation of prognosis and treatment benefit to inform decisions across all phases of treatment.</p><p><strong>Recommendations: </strong>The recommendations are organized to follow the longitudinal care of patients with stage I-III hormone receptor-positive, HER2-negative breast cancer, reflecting the sequence of decisions faced by clinicians from diagnosis through completion of systemic therapy. Endocrine therapy remains the foundation of treatment for stage I-III hormone receptor-positive, HER2-negative breast cancer. For selected patients, chemotherapy and targeted therapies can further reduce the risk of recurrence and breast cancer death. Treatment recommendations should integrate clinicopathologic features, genomic assays, patient preferences, treatment tolerability, and estimated recurrence risk. The guideline provides evidence-based recommendations to support individualized treatment selection and sequencing across the continuum of care.Additional information is available on the ASCO Publications website.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"101200JCO2602034"},"PeriodicalIF":44.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Patient Who Could Not Die.","authors":"Erika Ramsdale","doi":"10.1200/JCO-25-02505","DOIUrl":"https://doi.org/10.1200/JCO-25-02505","url":null,"abstract":"<p><p>An oncologist meets a patient who was never born and would never die and considers what AI can (and can't) teach about the art of connection.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502505"},"PeriodicalIF":44.7,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.","authors":"Youngju Song, Won Park, Hongryull Pyo, Yeon Joo Kim, Hanjong Ahn, Hwa Jung Kim, Young Seok Kim","doi":"10.1200/JCO-25-02234","DOIUrl":"https://doi.org/10.1200/JCO-25-02234","url":null,"abstract":"<p><strong>Purpose: </strong>To compare hypofractionated radiotherapy (RT) with conventional RT for treating biochemical recurrence following radical prostatectomy.</p><p><strong>Methods: </strong>Between 2019 and 2021, 316 patients with intermediate- to high-risk prostate cancer were randomly assigned to receive salvage RT with either 65 Gy in 26 fractions (hypofractionated RT, HYPO) or 66 Gy in 33 fractions (conventional RT, CONV). RT was delivered to the prostate bed, with elective pelvic nodal irradiation performed at the discretion of radiation oncologists. Intensity-modulated RT with daily image guidance was used. The primary end point was biochemical progression-free survival (bPFS). Secondary end points included distant metastasis-free survival (DMFS), prostate cancer-specific survival (CSS), toxicity profiles, and patient-reported quality-of-life.</p><p><strong>Results: </strong>One hundred fifty-one patients (51.2%) received androgen deprivation therapy, and 202 (68.5%) underwent elective nodal irradiation. Endorectal balloons were used in 186 men (63.1%). The median pre-RT prostate-specific antigen level was 0.36 ng/mL (IQR, 0.24-0.49 ng/mL). After a median follow-up of 52.6 months, the 4-year bPFS rates were 80.1% and 78.1% in the HYPO and CONV arms, respectively. There were no significant differences in DMFS (91.7% <i>v</i> 91.0%) and CSS (100% <i>v</i> 100%). The 4-year cumulative incidence of grade ≥2 GI toxicity was higher in the HYPO arm (7.9% <i>v</i> 0.7%), predominantly among patients without an endorectal balloon; all cases were resolved by the last follow-up. Patient-reported quality-of-life outcomes were comparable.</p><p><strong>Conclusion: </strong>bPFS was not superior in the HYPO arm at 4 years. However, given the comparable oncologic outcomes, toxicity profiles, and quality-of-life measures, hypofractionated RT may be considered a viable alternative in the salvage setting. Further research is needed to determine whether the use of an endorectal balloon reduces GI toxicity.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502234"},"PeriodicalIF":44.7,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.","authors":"Dan-Yun Ruan, Feng-Hua Wang, Yujuan Zhou, Yanqun Xiang, Jinguan Lin, Lin Liu, Ping Liu, Linquan Tang, Yuxiang Ma, Tao Hou, Qiuyan Chen, Zhi-Ming Li, Fei Han, Song Qu, Sufang Qiu, Chen Han, Hongzhi Ma, Fang Su, Jin Gao, Ye Guo, Zheng Wu, Hai-Jun Wu, Yanqiu Zhao, Meiyu Fang, Man Hu, Yuan Wu, Shuo Cui, Mengyun Li, Qiong Zhao, Rui-Hua Xu","doi":"10.1200/JCO-26-00640","DOIUrl":"https://doi.org/10.1200/JCO-26-00640","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti-PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combined with a PD-1 inhibitor pucotenlimab in this setting of patients.</p><p><strong>Materials and methods: </strong>Magic-C001 (ClinicalTrials.gov identifier: NCT05688605) is an ongoing, open-label, multicohort, dose escalation (phase I) and expansion (phase II) study in patients with EGFR-positive solid tumors. Eligible patients received pucotenlimab 3.0 mg/kg and BV at 1.8-2.3 mg/kg (phase I) or 2.0 mg/kg (phase II for NPC) once every 3 weeks. The primary end point for phase II was objective response rate (ORR). Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.</p><p><strong>Results: </strong>Among 31 patients with NPC at the recommended phase II dose (RP2D) from phase I and II who had received anti-PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0 to 85.8); DCR was 93.5% (95% CI, 78.6 to 99.2). The median DoR and PFS were 14.0 months (95% CI, 5.7 to not estimated) and 12.0 months (95% CI, 6.8 to 15.4), respectively. Median OS was not mature. Most common treatment-related adverse events (TRAEs) were pruritus (71.9%), hypoesthesia (65.6%), anemia (59.4%), and rash (56.3%). TRAEs of ≥grade 3 occurred in 40.6% of patients. No TRAEs led to death.</p><p><strong>Conclusion: </strong>To our knowledge, we report the first trial combining an ADC with immunotherapy for platinum and anti-PD-1/PD-L1-resistant NPC. BV plus pucotenlimab yielded a notable ORR with exceptionally durable responses and substantially prolonged PFS, alongside manageable toxicities. This regimen may offer a promising anti-PD-1 rechallenge strategy in this population, which is being confirmed in an ongoing, multicenter, randomized controlled, phase III study.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2600640"},"PeriodicalIF":44.7,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[¹⁸F]FDG PET-Negative Marrow: Results From an International Retrospective Study.","authors":"Federico Mercolini, Marissa Just, Barry L Shulkin, Natalie B Collins, Jacquelyn Crane, Douglas Harrison, Maria C Affinita, Wendy Allen-Rhoades, Alessandra Alessi, Sebastian D Asaftei, Michael A Arnold, Sonja Chen, Stefano Chiaravalli, Forrest FitzGerald, Martin T Freitag, Jessica L Iftner, Hedieh Khalatbari, Bart de Keizer, Irene von Luettichau, Christine Mauz-Körholz, Claudia Rossig, Guido Rovera, Stefan Rutkowski, Justin B Sims, Stephan D Voss, Ayami Yoshimi, Suzi Birz, Gianni Bisogno, Martin Ebinger, Johannes H M Merks, Monika Sparber-Sauer, Bernhard Haller, Aaron R Weiss, Corinne M Linardic, Reineke A Schoot, Simone Hettmer","doi":"10.1200/JCO-25-03080","DOIUrl":"https://doi.org/10.1200/JCO-25-03080","url":null,"abstract":"<p><strong>Purpose: </strong>Detection of bone marrow disease has been a major component of rhabdomyosarcoma (RMS) staging with bilateral bone marrow aspirates/biopsies (BMAB) from the iliac crests considered the diagnostic gold standard. This study's goal was to determine if 2-¹⁸F-labeled fluorodeoxyglucose positron emission tomography/computed tomography ([¹⁸F]FDG PET/CT) or PET/magnetic resonance imaging (MRI) may replace BMAB in RMS staging.</p><p><strong>Methods: </strong>Patients were recruited in Europe and North America. Medical records, FDG PET/CT or FDG PET/MRI (PET), and BMAB reports were collected retrospectively. Images were re-reviewed by nuclear medicine physicians at the patients' home institutions if PET reports indicated increased FDG uptake at bone/bone marrow sites or if tumor cells were detected in bone marrow samples.</p><p><strong>Results: </strong>PET imaging and BMAB were performed before chemotherapy and tumor resection in 301 patients with FDG-avid RMS. Bone marrow metastases were detected by PET and BMAB in 54, by PET only in 24, and by BMAB only in one of 301 patients with FDG-avid primary tumors. Absence of bone marrow metastases was confirmed by PET and BMAB in 222 of 301 patients. These observations translated into 98% sensitivity and 90% specificity for PET in detecting bone marrow metastases when BMAB was considered as gold standard. FDG-avid marrow disease was patchy (1-5 foci) in one third of cases. Patients with marrow disease indicated by PET and BMAB had more FDG-avid bone marrow foci, more metastatic sites, and lower survival than those with marrow disease indicated by PET only, suggesting more advanced disease stages.</p><p><strong>Conclusion: </strong>Bone marrow sampling may be omitted in patients without evidence of FDG-avid bone marrow disease by PET. If there are FDG-avid bone marrow lesions, further investigation by MRI and/or biopsy should be considered.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2503080"},"PeriodicalIF":44.7,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.","authors":"Erin M Mobley, David R Doody, Steven D Colan, Sanjeev Aggarwal, Richard Aplenc, Saro H Armenian, K Scott Baker, Smita Bhatia, Louis S Constine, David R Freyer, Lisa M Kopp, Wendy M Leisenring, Nao Sasaki, Lynda M Vrooman, Barbara L Asselin, Cindy L Schwartz, Eric J Chow, Steven E Lipshultz","doi":"10.1200/JCO-26-02036","DOIUrl":"https://doi.org/10.1200/JCO-26-02036","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2602036"},"PeriodicalIF":44.7,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148813163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response?","authors":"Fahima Dossa, Trevor Yeung, Julio Garcia-Aguilar","doi":"10.1200/JCO-25-01752","DOIUrl":"10.1200/JCO-25-01752","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2266-2270"},"PeriodicalIF":44.7,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.","authors":"Ross A Abrams, Kathryn A Winter, Karyn A Goodman, William F Regine, Howard P Safran, Chandan S Guha, Lisa A Kachnic, Michael T Gillin, Philip A Philip, Andrew M Lowy, Eileen O'Reilly, Jean-Luc Van Laethem, Samantha A Seaward, Abraham J Wu, Jennifer J Wu, Raid M Aljumaily, Thomas A DiPetrillo, Ravit Geva, Pramila Rani Anne, Darla K Liles, Diane C Ling, Alison Conlin, Jennifer Moughan, Christopher H Crane","doi":"10.1200/JCO-25-02520","DOIUrl":"10.1200/JCO-25-02520","url":null,"abstract":"<p><strong>Purpose: </strong>To assess whether adding fluoropyrimidine sensitized radiotherapy (CXRT) to adjuvant chemotherapy improves overall survival (OS) after curative intent resection of the pancreatic head.</p><p><strong>Methods: </strong>This was a multicenter, randomized phase III, two step trial. Step 1: gemcitabine versus gemcitabine + erlotinib (previously reported). Step 2: random assignment to sixth chemotherapy cycle ± CXRT after five cycles of step 1 chemotherapy without progression. Outcomes of step 2 random assignment are reported here. Assuming 17 months median OS (chemotherapy alone), the sample size was 354 patients (hazard ratio [HR], 0.76, 80% power, one-sided α = .05, 316 OS events). OS/disease-free survival (DFS) were estimated by Kaplan-Meier and arms compared using the log-rank test.</p><p><strong>Results: </strong>A total of 354 patients (median age 63, 55% male, 56% performance status, 1) were randomly assigned to chemotherapy (174) or chemotherapy + CXRT (180). Univariable median and 5-year OS (90% CIs) were 2.6 years (2.1-3.1) and 23.1% (17.7-28.6) for chemotherapy alone, and 2.3 years (2.0-2.6) and 27.9% (22.2-33.6) for chemotherapy + CXRT. The OS primary end point was not met (HR, 0.96 [90% CI, 0.79 to 1.18]; one-sided <i>P</i> = .38, two-sided <i>P</i> = .77). Chemotherapy + CXRT was associated with a trend for improved DFS (univariably; HR, 0.82 [95% CI, 0.65 to 1.03]; <i>P</i> = .089), without increase in grade 4/5 toxicities. However, grade 3 toxicity increased (38% <i>v</i> 19%, <i>P</i> < .001). Significantly, treatment by nodal status interactions showed that CXRT improved OS (<i>P</i> = .0063) and DFS (<i>P</i> = .014) in node-negative patients.</p><p><strong>Conclusion: </strong>Overall, the addition of adjuvant CXRT to adjuvant gemcitabine did not statistically significantly improve OS, DFS, or increase grade 4/5 toxicity. For node-negative patients, CXRT improved OS and DFS. These results, if confirmed in studies with current or future systemic therapies, would support the use of adjuvant/neoadjuvant CXRT for node-negative patients.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2316-2328"},"PeriodicalIF":44.7,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13374715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.","authors":"Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, Kate Cwynarski, Chan Y Cheah, Tarec C El-Galaly, Diego Villa, Kerry J Savage, Paola Ghione, Sabela Bobillo, Karin E Smedby, Sara Harrysson, Marek Trneny, Magdalena Klanova, Robert Puckrin, Christopher P Fox, Mark Bishton, Gita Thanarajasingam, Nicole Wong Doo, Greg Hapgood, Carole Soussain, Sylvain Choquet, Michael Dickinson, Dipti Talaulikar, Sanjay de Mel, Gavin Preston, Matthew Ahearne, Eliza A Hawkes, Elisabeth Schorb, Aline Clavert, Matthew Ku, Anna Guidetti, Mayur Narkhede, Teresa Calimeri, Eric Durot, Jeffrey Smith, Loïc Renaud, Pamela McKay, Toby A Eyre","doi":"10.1200/JCO-26-00947","DOIUrl":"10.1200/JCO-26-00947","url":null,"abstract":"<p><strong>Purpose: </strong>In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients.</p><p><strong>Methods: </strong>Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the following criteria: CNS international prognostic index score 5-6; testicular, renal/adrenal, or breast involvement; ≥3 extranodal sites), treated with or without HD-MTX. The primary outcome was CNS relapse rate (isolated or concurrent with systemic relapse) measured from diagnosis with additional landmark analysis of all responding patients with no progression event at 6 months.</p><p><strong>Results: </strong>Analyses were performed on 1,923 patients meeting UHR criteria. No significant difference in 3-year CNS relapse rate was observed between no HD-MTX (n = 1,051) versus HD-MTX patients (n = 872), including in multivariable analyses adjusting for baseline characteristics (3-year rate, 9.3% <i>v</i> 8.1%; adjusted hazard ratio [HR], 1.13 [95% CI, 0.82 to 1.57]). Analyses restricted to isolated CNS relapse also confirmed no difference (5.9% <i>v</i> 5.7%; adjusted HR, 1.03 [95% CI, 0.69 to 1.53]). In the landmark analysis (no HD-MTX n = 782, HD-MTX n = 773), no difference in 3-year CNS relapse was observed (6.7% <i>v</i> 6.6%, adjusted HR, 0.95 [95% CI, 0.62 to 1.44]).</p><p><strong>Conclusion: </strong>To our knowledge, this is the largest international comparative data set of patients with LBCL with UHR features showing no significant reduction in CNS relapse with HD-MTX in all UHR or in any individual subgroup. Despite inherent limitations of retrospective analyses, the data strongly support previous studies in suggesting HD-MTX prophylaxis has no meaningful benefit for most patients.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2290-2302"},"PeriodicalIF":44.7,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13489768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection.","authors":"Risako Komata, Kenju Ando, Akihiko Shimomura, Chikako Shimizu","doi":"10.1200/JCO-26-00140","DOIUrl":"10.1200/JCO-26-00140","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"2356"},"PeriodicalIF":44.7,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}